Follow-up study of pneumococcal vaccine given in infancy
Part of Infections clinical trials.
This study checks how well a pneumococcal vaccine (which protects against a common bacterial infection) continues to work in children who received it as infants about 4 or more years ago. Researchers will take blood samples to measure immune protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child participated in the original 13-valent pneumococcal vaccine trial when they were 2 months old
- At least 4 years have passed since your child's last vaccine dose from the original trial
- Your child had blood draws at 1 and 2 years after the original vaccination
- Your child has not received any other pneumonia vaccines since completing the original series
- Your child's temperature is below 37.3°C (99.1°F) on the screening visit
- You can provide identification and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
This trial tests a new vaccine designed to protect against 24 types of pneumococcal bacteria (which cause pneumonia and other serious infections). Researchers are checking if it's safe and how well it works in infants, children, and adults.
This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.
This study tests a pneumococcal vaccine (PCV13) in healthy 2-month-old babies to see if it is safe and helps protect against pneumococcal infections. Your baby would receive the vaccine and be monitored for any side effects.
This trial tests a new vaccine called V118C to protect children against pneumococcal disease. It is for two age groups: toddlers aged 12-15 months who already had 3 doses of a standard pneumococcal vaccine, and babies about 2 months old who have not had any pneumococcal vaccine yet.
This study tests a new pneumococcal vaccine (PCV24) for babies ages 2 to 23 months. It aims to see if the vaccine is safe and helps protect against serious infections like pneumonia and meningitis.
Hear when a new Pneumococcal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.